Article Text

Download PDFPDF

CT-01 Association between hydroxychloroquine non-adherence and disease activity in a predominantly hispanic systemic lupus erythematosus cohort
  1. Kayla Neville+,
  2. George Danias+,
  3. Teja Kapoor,
  4. Jon Giles,
  5. Laura Geraldino-Pardilla and
  6. Anca Askanase
  1. Columbia University College of Physicians and Surgeons, New York, NY, USA
  2. +These authors share first authorship


Background Hydroxychloroquine (HCQ) is a key component of therapy for Systemic Lupus Erythematosus (SLE). Medication non-adherence is reported in 40%–80% of lupus patients and results in increased morbidity, mortality, and health care utilization. HCQ levels are a sensitive and reliable method to assess medication adherence. Our study evaluated the feasibility of HCQ level measurement in a routine clinical setting and its association with disease activity in a predominantly Hispanic population.

Abstract CT-01 Table 1

Patient characteristics by adherence status

Methods SLE patients from the Columbia University Lupus cohort, treated with HCQ for ≥6 months and reporting medication-adherence were included. HCQ levels were measured by whole blood high performance liquid chromatography. Non-adherence was defined as HCQ level <500 ng/ml. Univariable and multivariable regression models were constructed to evaluate the association between HCQ level and disease activity measured by SLEDAI-2K.

Results One-hundred and eight patients were enrolled (table 1); the mean age was 38 years, 91% were female, and 62% were Hispanic. The average SLEDAI-2K was 4.3 (0–20). Forty-one percent of patients had HCQ levels<500 ng/ml consistent with non-adherence, of whom 19% had undetectable levels. A higher SLEDAI-2K score was associated with low HCQ levels (p<0.001). This association remained significant after adjusting for age, sex, race/ethnicity, education, primary language, glomerular filtration rate, depression, smoking, major organ involvement, steroid use, and immunosuppression (p<0.004).

Conclusions HCQ levels <500 ng/ml were associated with higher disease activity and accounted for 32% of the SLEDAI variability. HCQ levels are a simple and reliable method to evaluate medication adherence in SLE. Levels <500 ng/ml should be discussed with patients and the reasons for non-adherence should be further explored and addressed.

Acknowledgements We acknowledge the patients who participated in this study.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.